Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CARDIOVASCULAR DISEASE

Targeting ASGR1 to lower cholesterol

New research reports that targeting the asialoglycoprotein receptor (ASGR1) in mice promotes cholesterol excretion through a mechanism involving stabilization of LXR without lipogenesis activation, strengthening the idea of therapeutically targeting ASGR1 to lower blood cholesterol and risk of atherosclerotic cardiovascular disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Uptake of circulating asialoglycoproteins (AGPs) via ASGR is linked to hepatic cholesterol metabolism.

References

  1. Rader, D. J. Cell Metab. 23, 405–412 (2016).

    Article  CAS  Google Scholar 

  2. Nurmohamed, N. S., Navar, A. M. & Kastelein, J. J. P. Am. Coll. Cardiol. 77, 1564–1575 (2021).

    Article  CAS  Google Scholar 

  3. Nioi, P. et al. N. Engl. J. Med. 374, 2131–2141 (2016).

    Article  CAS  Google Scholar 

  4. Wang, J. Q. et al. Nature https://doi.org/10.1038/s41586-022-05006-3 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Igdoura, S. A. Curr. Opin. Lipidol. 28, 209–212 (2017).

    Article  CAS  Google Scholar 

  6. Rensen, P. C. N. et al. J. Med. Chem. 47, 5798–5808 (2004).

    Article  CAS  Google Scholar 

  7. Springer, A. D. & Dowdy, S. F. Nucleic Acid Ther. 28, 109–118 (2018).

    Article  CAS  Google Scholar 

  8. Samuel, E. et al. Ann. Pharmacother. https://doi.org/10.1177/10600280221105169 (2022).

    Article  PubMed  Google Scholar 

  9. Barton, A. R. et al. Nat. Genet. 53, 1260–1269 (2021).

    Article  CAS  Google Scholar 

  10. van den Boogert, M. A. W. et al. Curr. Opin. Lipidol. 28, 502–506 (2017).

    Article  Google Scholar 

  11. Rosenson, R. S. et al. Circulation 125, 1905–1919 (2012).

    Article  Google Scholar 

  12. Zhang, Y. et al. J. Clin. Invest. 122, 1688–1699 (2012).

    Article  CAS  Google Scholar 

  13. Russo-Savage, L. & Schulman, I. G. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166121 (2021).

    Article  CAS  Google Scholar 

  14. William Hancock-Cerutti, W. & Rader, D. J. J. Am. Coll. Cardiol. 63, 2129–2130 (2014).

    Article  Google Scholar 

  15. Cohen, J. C. & Hobbs, H. H. Science 340, 689–690 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel J. Rader.

Ethics declarations

Competing interests

D.J.R. serves on the scientific advisory boards of Alnylam, Novartis, Pfizer and Verve.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rader, D.J. Targeting ASGR1 to lower cholesterol. Nat Metab 4, 967–969 (2022). https://doi.org/10.1038/s42255-022-00623-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-022-00623-8

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research